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Abstract Procollagenase-3 (proMMP-13) can be activated by
soluble or cell associated membrane type matrix metalloprotein-
ase 1 (MT1-MMP). In this study we show that the cell based
activation of proMMP-13 by MT1-MMP was dependent on the
C-terminal domain, as v249451 proMMP-13, which lacks the
haemopexin domain, and a chimaera from N-terminal MMP-13
and C-terminal MMP-19 (proMMP-13/19) were not processed
by MT1-MMP expressing cells. Only the initial cleavage at
Gly35^Ile36 was dependent on MT1-MMP activity, as conver-
sion to the active enzyme (Tyr85 N-terminus) required a func-
tional MMP-13 active site. Unlike proMMP-2 activation, this
process was independent of tissue inhibitor of metalloproteinase-
2 (TIMP-2) as MT1-MMP expressing cells from the TIMP-
23/3 mouse e⁄ciently activated proMMP-13.
4 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Human procollagenase-3 (proMMP-13) is a member of the
collagenase subfamily of matrix metalloproteinases (MMPs)
and is expressed in breast tumours, hypertrophic chondrocytes
and skin ¢broblasts in vivo [1^3]. One important mechanism
for the regulation of the collagenolytic activity of MMP-13 in
vivo is the activation of the respective proenzyme by extracel-
lular events. MMP-13 is an inactive proenzyme [4,5], therefore
the unravelling of physiologically relevant activation path-
ways represents an important topic of investigation. We
have shown that active MMP-3, gelatinase A (MMP-2) and
membrane type MMP (MT1-MMP) mediate proMMP-13 ac-
tivation in vitro and in cell model systems [6]. It is, however,
not clear to date which domains of proMMP-13 contribute to
the MT1-MMP driven activation of the proenzyme at the cell
surface and whether there is a contribution of tissue inhibitor
of metalloproteinase-2 (TIMP-2) in this process. The activa-
tion of proMMP-2 by cell bound MT1-MMP involves the
establishment of a complex between TIMP-2 and MT1-
MMP that forms a ‘receptor’ which binds the C-terminal do-
main of proMMP-2 to the C-terminal domain of TIMP-2 [7].
In this study we assess the role of the C-terminal domain of
proMMP-13 and of TIMP-2 in regulating MT1-MMP depen-
dent activation of proMMP-13 at the cell surface. In conjunc-
tion with data evaluating the signi¢cance of autolytic proteol-
ysis of proMMP-13 in this process we extend our knowledge
of cellular activation of proMMP-13 by MT1-MMP.
2. Materials and methods
2.1. Expression and puri¢cation of recombinant MMPs and TIMPs
proMMP-13, the C-terminal deletion mutant of MMP-13 (v249451
proMMP-13), proMMP-2, TIMP-1 and TIMP-2 were puri¢ed as pub-
lished [4,8^10]. A chimaeric enzyme was constructed from N-terminal
MMP-13 and C-terminal MMP-19 (proMMP-13/19) by ligating the
XcmI to EcoRI C-terminal domain fragment of MMP-19 into the
pEE12 vector carrying the coding sequences of the N-terminal domain
of proMMP-13. Stable NS0 cell lines were generated and proMMP-
13/19 was puri¢ed using SP-Sepharose [4].
2.2. Generation of pEE12 E205-A proMMP-13
A pEE12 expression vector for an inactive mutant of proMMP-13
(E205-A) was generated by extension mutagenesis. Two PCR products
were generated using the mutagenic primers: 5P-GTGGCCGAATG-
CATGCGCAGCAACAAGAAACAAG-3P and 5P-CTGCGCATG-
CATTCGGCCACTCCTTAGGTCTTG-3P, in conjunction with two
vector primers and proMMP-13 cDNA as the template. The PCR
products were overlap extended using vector primers and the product
was cleaved with HindIII and ligated into pEE12. The cDNA se-
quence was veri¢ed by dideoxy sequencing.
2.3. Cellular model systems to investigate the activation of proMMP-13
by MT1-MMP overexpressing cells
2.3.1. HT1080 cells constitutively overexpressing MT1-
MMP. HT1080 cells transfected with MT1-MMP in the HCMV/
gpt vector, pGWIH9, were from British Biotechnology [7]. They
make 1.5 pmol MT1-MMP per mg of membrane protein or vector
control cells (0.13 pmol MT1-MMP per mg membrane protein) and
were cultured as described [7].
2.3.2. Inducible MT1-MMP overexpressing HTC75 ¢brosarcoma
cells. The HTC75 cell line, which carries the pTET o¡ control ele-
ment, was transfected with the human MT1-MMP cDNA in pTRE
and the pSV2neo plasmid as a selective marker [11,12]. proMMP-13
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activation was performed following induction of MT1-MMP expres-
sion for 24 h in doxycycline free medium. Cells produce s 10 times
the endogenous level of MT1-MMP [12].
2.3.3. MT1-MMP overexpressing ¢broblasts from the TIMP-23/3
mice. Immortalised TIMP-23/3 mouse ¢broblasts [13,14] were
transfected with PvuI linearised MT1-MMP cDNA in pcDNA3.1
zeo(+) and stable cell lines were established following selection with
250 Wg/ml zeocin in Dulbecco’s modi¢ed Eagle’s medium (DMEM),
10% foetal calf serum and 2 mM glutamine.
2.4. Cellular activation experiments
Cells were seeded into 24 well plates at a density of 5U104 cells/well
and grown for 24 h in each appropriate medium. Each well was
supplemented with 100 ng puri¢ed proMMP-13 in 300 Wl serum-free
DMEM and, where desired, some wells were complemented with
TIMP-1 and TIMP-2, or the serine proteinase inhibitor aprotinin in
order to analyse their role in cellular activation. Alternatively, activa-
tion experiments were also performed by transfection of pEE12
proMMP-13 and E205-A proMMP-13 (0.5 Wg/well) into the MT1-
MMP overexpressing cell lines using FuGENE 6. After 24 h, the
medium was replaced with 300 Wl/well serum free medium and incu-
bated for a further 24 h.
2.5. Western blotting
A 20 Wl aliquot of medium was removed and analysed on 10%
SDS^PAGE followed by Western blotting. Blots were incubated
with an antiserum to proMMP-13 and visualised using a peroxidase
conjugated secondary antibody and chemiluminescent substrate.
3. Results
3.1. Characterisation of proMMP-13 activation by HT1080
and HTC75 cells expressing MT1-MMP
HT1080 cells expressing MT1-MMP were supplemented
with recombinant proMMP-13 and incubated for 24 h to
analyse proMMP-13 activation. proMMP-13 was activated
via an intermediate 56 kDa to the ¢nal active 48 kDa form
(Fig. 1, lane 5), while vector control cells were unable to
activate proMMP-13 (Fig. 1, lane 1). Activation was not af-
fected by the serine proteinase inhibitor aprotinin (lane 6),
and partially inhibited by TIMP-1 (lane 7). TIMP-2 inhibited
activation e⁄ciently since it is a potent inhibitor of MT1-
MMP (lane 8). Coexpression of proMMP-13 in HTC75 cells
expressing MT1-MMP also resulted in e⁄cient activation
(Fig. 2, lane 2) and we frequently observed fragmentation
products of Mr 29 kDa and Mr 27 kDa in these experiments
which represent the catalytic and C-terminal domains of
MMP-13 respectively (Fig. 2, lane 2, low molecular mass
bands). This indicated that proMMP-13 activation in
HTC75 cells was more e⁄cient, as MMP-13 fragmentation
only occurs at relatively high concentrations of active enzyme
[8]. These MT1-MMP expressing cell models allowed us to
establish the role of the C-terminal domain and the active
site in proMMP-13 activation by cell surface MT1-MMP.
3.2. Cellular activation of proMMP-13 is a two step event
In order to assess whether the secondary cleavage event
observed during proMMP-13 activation (Fig. 1, lanes 5, 6
and 7) was autoproteolytic we transfected HTC75 cells with
pEE12 E205-A proMMP-13 and analysed activation by West-
ern blotting. E205-A proMMP-13 was processed mainly to the
56 kDa intermediate form (Fig. 2, lane 4, arrowhead), with
minute amounts of active enzyme detectable, suggesting that
e⁄cient conversion to the 48 kDa form required catalytically
competent MMP-13. The small amounts of active form may
be due to the action of MMP-2, which is less e⁄cient. In
contrast, wild type proMMP-13 was e⁄ciently converted to
the 48 kDa active form which underwent further fragmenta-
tion (Fig. 2, lane 2) [8].
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Fig. 1. Activation of proMMP-13 by HT1080 cells transfected with
MT1-MMP. Western blot developed with an antibody to proMMP-
13. Lane 1, HT1080 cells transfected with vector supplemented with
5.5 nM proMMP-13 were incubated for 24 h at 37‡C; lane 2, as
lane 1 with 2 WM aprotinin; lane 3, as lane 1 with 11 nM TIMP-1;
lane 4, as lane 1 with 15 nM TIMP-2; lane 5, HT1080 cells trans-
fected with MT1-MMP supplemented with 5.5 nM proMMP-13;
lane 6, as lane 5 with 2 WM aprotinin; lane 7, as lane 5 with 11 nM
TIMP-1; lane 8, as lane 5 with 15 nM TIMP-2. Bands correspond-
ing to proMMP-13 (black arrow), active MMP-13 and the activa-
tion intermediate (arrowhead) are indicated.
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Fig. 2. Processing of E205-A proMMP-13 by MT1-MMP expressing
cells. HTC75 cells transfected with pEE12 proMMP-13 or the inac-
tive E205-A proMMP-13 mutant were incubated at 37‡C for 24 h
following induction of MT1-MMP expression. Lane 1, non-induced
proMMP-13 transfected; lane 2, induced proMMP-13 transfected;
lane 3, non-induced E205-A proMMP-13 transfected; lane 4, induced
E205-A proMMP-13 transfected. Protein bands corresponding to
proMMP-13, active MMP-13 and the activation intermediate are in-
dicated on the right. A C-terminal fragmentation product is ob-
served in lane 2, band corresponding to Mr 27 kDa.
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Fig. 3. C-terminal domain dependent activation of proMMP-13 by
MT1-MMP membranes. proMMP-13, a chimaeric proMMP-13/19
mutant and v249451 proMMP-13 at concentrations of 5.5 nM were
incubated with MT1-MMP containing membranes for 16 h at 37‡C.
Lane 1, proMMP-13 bu¡er control; lane 2, proMMP-13 with MT1-
MMP membranes; lane 3, proMMP-13/19 bu¡er control; lane 4,
proMMP-13/19 with MT1-MMP membranes; lane 5, v249451
proMMP-13 bu¡er control; lane 8, v249451 proMMP-13 with MT1-
MMP membranes. The protein bands corresponding to proenzymes
are indicated with arrows.
FEBS 26765 19-11-02
V. Kna«uper et al./FEBS Letters 532 (2002) 127^130128
3.3. C-terminal domain dependent activation of proMMP-13 by
membrane associated MT1-MMP
To determine whether the C-terminal domain of proMMP-
13 regulates MT1-MMP activation, as described for
proMMP-2, we investigated whether a chimaeric proenzyme
proMMP-13/19 or a C-terminal deletion mutant of proMMP-
13 (v249451 proMMP-13) were activated by MT1-MMP con-
taining membranes. Only wild type proMMP-13 was pro-
cessed to the fully active enzyme (Fig. 3, lanes 2 and 4), while
proMMP-13/19 (lane 5) and v249451 proMMP-13 (lane 7)
were not activated. Identical results were obtained when cells
transfected with MT1-MMP were employed to activate wild
type and mutant proMMP-13 preparations (not shown).
These results indicate that the C-terminal domain of
proMMP-13 is essential for cellular activation by MT1-MMP.
3.4. TIMP-2 independent processing of proMMP-13 by MT1-
MMP expressing cells from the TIMP-23/3 mouse
To address whether the TIMP-2 component of the MMP-2
activation cascade was required for direct proMMP-13 acti-
vation we performed experiments using cells derived from the
TIMP-23/3 mouse, which express MT1-MMP. proMMP-13
activation proceeded e⁄ciently in the absence of TIMP-2 (Fig.
4, lane 2). Addition of TIMP-2, at concentrations that would
potentiate MMP-2 activation, inhibited proMMP-13 activa-
tion. Addition of proMMP-2 to the cells in the presence of
TIMP-2 potentiated proMMP-13 activation (Fig. 4) [6,5].
4. Discussion
We have previously characterised the activation of
proMMP-13 by MT1-MMP in solution and in cell model
systems such as concanavalin A stimulated ¢broblasts or cy-
tokine and phorbol myristate acetate stimulated SW1353
chondrosarcoma cells [5,6]. Here we have examined the po-
tential parallels between cell based proMMP-13 activation
and that elucidated for proMMP-2. Using HT1080 cells over-
expressing MT1-MMP we showed that proMMP-13 (60 kDa)
was processed via a 56 kDa intermediate to the fully active 48
kDa active enzyme and that production of the intermediate
was TIMP-1 insensitive. The initial cleavage to the 56 kDa
intermediate (Ile36 N-terminus) was mediated by MT1-MMP
activity. This was con¢rmed using catalytically inactive E205-A
proMMP-13 which was processed by MT1-MMP to the 56
kDa intermediate. Further processing to the 48 kDa active
enzyme required a functional active site, i.e. the secondary
cleavage is autoproteolytic. This resembles the activation of
proMMP-2 by MT1-MMP or MT2-MMP which also requires
an initial cleavage by either MT-MMP within the propeptide
domain of proMMP-2 prior to autoproteolytic cleavage gen-
erating fully active enzyme [15,16].
The activation of proMMP-13 by cell associated MT1-
MMP required the presence of its C-terminal domain, since
a C-terminal domain deletion mutant or a form of the enzyme
where the C-terminal domain had been replaced with that of
MMP-19 were not activated. These ¢ndings resemble data on
proMMP-2 activation by MT1-MMP and MT2-MMP, which
depends on the C-terminal domain of MMP-2 [17,18]. MT1-
MMP mediated activation of proMMP-2 requires the estab-
lishment of a trimolecular complex between MT1-MMP,
TIMP-2 and proMMP-2 where the C-terminal domain of
TIMP-2 interacts with the C-terminal domain of proMMP-2
[19]. This is re£ected in the strength of the MMP-2 and
TIMP-2 inhibitor interactions [10].
We established the role of TIMP-2 in the cell-based MT1-
MMP activation of proMMP-13 relative to proMMP-2. Fi-
broblasts derived from TIMP-23/3 mice expressing MT1-
MMP activated proMMP-13, in contrast to proMMP-2 which
cannot be processed in these cells [13,20]. We can conclude
that the C-domain of proMMP-13 is TIMP-2 independent
and that proMMP-13 activation by MT1-MMP does not in-
volve the establishment of a trimolecular complex between
proMMP-13, MT1-MMP and TIMP-2. Our data re£ect the
results from the recent X-ray analysis of the proMMP-2/
TIMP-2 complex [21]. As the majority of the residues involved
in hydrophobic and electrostatic interactions at the complex
interphase are not conserved in the C-terminal domain of
proMMP-13, the highly positively charged lysine cluster (res-
idues 547^575) at the end of blade 3 of the C-terminal L-pro-
peller is absent in MMP-13, underlining why TIMP-2 fails to
potentiate proMMP-13 activation by MT1-MMP. The addi-
tion of low doses of TIMP-2, which potentiate proMMP-2
activation by the MT1-MMP transfected ¢broblasts from
the TIMP-23/3 mice, had a small but detectable e¡ect on
the amounts of proMMP-13 being activated, indicating that
this was probably mediated by MMP-2 activity. Furthermore,
we were able to detect some fully processed MMP-13 in ex-
periments where we transfected the cells with the E205-A
proMMP-13 mutant. We conclude that MMP-2 plays an aux-
iliary role in converting the intermediate form (56 kDa) into
the fully active form.
Studies by Morrison et al. [18] showed that cellular activa-
tion experiments with a C-terminal domain deletion mutant of
proMMP-2 showed complete lack of activation and cell sur-
face association and that the MT2-MMP mediated activation
of proMMP-2 is only partially inhibited by the C-terminal
domain of MMP-2 (500-fold molar excess) [18]. We obtained
similar data for proMMP-13 activation by MT1-MMP ex-
pressing cells (not shown) and we hypothesise that, although
the C-terminal domain is required for activation, the interac-
tions involved are weak and that other domains of proMMP-
13 may also contribute to allow processing by MT1-MMP. In
cross-linking studies on HTC75 cells overexpressing MT1-
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Fig. 4. Activation of proMMP-13 by TIMP-23/3 mouse ¢broblasts
expressing MT1-MMP. TIMP-23/3 mouse ¢broblasts expressing
MT1-MMP were transfected with proMMP-13 and incubated for 24 h
with di¡erent concentrations of TIMP-2. Lane 1, vector control
cells ; lane 2, MT1-MMP transfected cells ; lanes 3^8, MT1-MMP
transfected cells incubated with 1 nM, 5 nM, 10 nM, 20 nM, 40
nM and 80 nM TIMP-2. Lanes 9 and 10, MT1-MMP transfected
cells incubated with 1 nM TIMP-2 and 1.7 nM proMMP-2 (lane 9)
and 3.5 nM proMMP-2 (lane 10); lanes 11 and 12, MT1-MMP
transfected cells incubated with 5 nM TIMP-2 and 1.7 nM
proMMP-2 (lane 11) and 3.5 nM proMMP-2 (lane 12). Protein
bands corresponding to proMMP-13 and active MMP-13 are indi-
cated on the right.
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MMP exposed to exogenous MMP-13, we were unable to
identify any MMP-13 complexes by either immunoblotting
or immunoprecipitation (data not shown). We have recently
ruled out that Endo180/urokinase type plasminogen activator
receptor associated protein is a MMP-13 ‘receptor’ in MT1-
MMP activation of proMMP-13 [22] and thus other binding
or interacting partners may be involved in this process. The
nature of the binding partner for proMMP-13 binding to the
cell surface allowing MT1-MMP mediated processing has yet
to be established.
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